Annex 1 contamination control now demands sustained attention beyond the initial implementation project. The revised EU GMP Annex 1 came into operation on 25 August 2023, with paragraph 8.123 following on 25 August 2024. For manufacturers in 2026, the useful question is whether the controls established during implementation still reflect the facility, its processes and its current risks.
The lessons discussed here are practical conclusions drawn from the guidance and quality management principles. They are not a claim that every manufacturer has encountered the same problems. Each site needs to test these considerations against its own evidence, especially where production has changed since its original gap assessment.
A contamination control strategy needs operational ownership
Annex 1 calls for a facility-wide contamination control strategy, or CCS, that brings together critical controls and monitoring measures and is actively reviewed. It also makes clear that monitoring or testing alone cannot assure sterility. The practical implication is that the CCS needs to explain how contamination is prevented during real operations.
One useful review exercise is to select a routine material transfer and follow it physically through the facility. Compare the actual sequence with the CCS, the transfer procedure and the qualification evidence. If staff need an undocumented workaround, the priority is to understand why the documented arrangement does not meet the operational need.
Ownership should extend across production, engineering, microbiology and QA. A strategy managed only as a quality document can become detached from equipment changes or maintenance decisions. Agree which changes require a CCS impact assessment and make that assessment part of the existing decision process.
Risk assessments should reveal uncertainty
ICH Q9(R1) addresses the influence of subjectivity in quality risk management and the importance of scientific knowledge and appropriate formality. That provides a useful lens for revisiting contamination risk assessments written during a busy implementation period.
For example, a hypothetical assessment may classify an intervention as low risk because experienced operators perform it. The assessment becomes more useful when it explains the intervention’s duration, location, exposure and supporting evidence. Experience is relevant, but the conclusion should remain understandable to someone who was not present when it was agreed.
QA should encourage teams to record what they do not yet know. An uncertain assumption can lead to a targeted study or additional observation. Treating uncertainty as a reason to gather evidence helps prevent optimistic scoring from becoming embedded in the site’s control strategy.
Investigations should test the whole explanation
A contamination investigation can lose value when its conclusion focuses on the most visible event. An operator movement may be relevant, but investigators should also consider whether transfer arrangements, equipment condition or procedural ambiguity made that movement necessary.
FDA’s aseptic processing guidance addresses investigations of microbiological contamination and the need to evaluate potential causes thoroughly. For QA teams, the lesson is to ask whether the proposed cause explains all the available observations. If it explains only one result while leaving related evidence unresolved, further work may be needed.
Corrective and preventive actions should be linked to that explanation. Retraining may be appropriate where a knowledge or execution gap is demonstrated. Where the problem arises from an awkward process design, the action should address the design. An effectiveness review should examine whether the relevant risk has reduced under normal working conditions.
Connect local signals with management decisions
Environmental monitoring results, intervention records and maintenance observations can tell different parts of the same story. As a practical recommendation, sites should review selected signals together when investigating recurring events, rather than allowing departmental boundaries to determine the scope of the discussion.
ICH Q10 describes a pharmaceutical quality system that includes process monitoring, CAPA, change management and management review. Applying that structure means contamination control findings should influence decisions about resources and improvement priorities. Repeated concern about a transfer step, for example, should reach the people able to approve a better arrangement.
A useful management review asks what has changed since the previous assessment, which actions remain incomplete and whether the evidence supports the current controls. It should also examine how quickly significant issues reach decision-makers. A technically sound recommendation has limited value if ownership or funding remains unresolved.
Revisit implementation through current evidence
Annex 1 contamination control should develop as the facility develops. A focused reassessment can begin with one process, its recent changes and its unresolved risks. That is often more productive than revising the entire CCS before deciding which operational questions need answers.
QA Resources offers support in quality audits, quality risk management, validation and documentation. Contact the team to discuss an independent review of your contamination control arrangements or the specialist expertise needed to translate identified gaps into practical improvement work.